Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 454

1.

Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.

Mahato RI, Cheng K, Guntaka RV.

Expert Opin Drug Deliv. 2005 Jan;2(1):3-28. Review.

PMID:
16296732
2.

Approaches for the sequence-specific knockdown of mRNA.

Scherer LJ, Rossi JJ.

Nat Biotechnol. 2003 Dec;21(12):1457-65. Review.

PMID:
14647331
3.

RNA interference detected 20 years ago?

Schmidt FR.

Nat Biotechnol. 2004 Mar;22(3):267-8. No abstract available.

PMID:
14990942
4.

Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo.

Mook OR, Baas F, de Wissel MB, Fluiter K.

Mol Cancer Ther. 2007 Mar;6(3):833-43.

5.

Nucleic acid-based techniques for post-transcriptional regulation of molecular targets.

Jarad G, Simske JS, Sedor JR, Schelling JR.

Curr Opin Nephrol Hypertens. 2003 Jul;12(4):415-21. Review.

PMID:
12815338
6.

Antisense technology: a selective tool for gene expression regulation and gene targeting.

Sahu NK, Shilakari G, Nayak A, Kohli DV.

Curr Pharm Biotechnol. 2007 Oct;8(5):291-304. Review.

PMID:
17979727
7.

PNA oligomers as tools for specific modulation of gene expression.

Pooga M, Land T, Bartfai T, Langel U.

Biomol Eng. 2001 Jun;17(6):183-92. Review.

PMID:
11337277
8.

Progress in the development of nucleic acid therapeutics for cancer.

Kalota A, Shetzline SE, Gewirtz AM.

Cancer Biol Ther. 2004 Jan;3(1):4-12. Epub 2004 Jan 18. Review.

PMID:
14726654
9.

Anti-genes: siRNA, ribozymes and antisense.

Scanlon KJ.

Curr Pharm Biotechnol. 2004 Oct;5(5):415-20. Review.

PMID:
15544489
10.

Tomato transgene structure and silencing.

Sanders RA, Hiatt W.

Nat Biotechnol. 2005 Mar;23(3):287-9. No abstract available.

PMID:
15765076
11.

Antisense and RNA interference approaches to target validation in pain research.

Kurreck J.

Curr Opin Drug Discov Devel. 2004 Mar;7(2):179-87. Review.

PMID:
15603251
12.

RNA interference: a potent tool for gene-specific therapeutics.

Ichim TE, Li M, Qian H, Popov IA, Rycerz K, Zheng X, White D, Zhong R, Min WP.

Am J Transplant. 2004 Aug;4(8):1227-36. Review.

13.

RNAi: a novel antisense technology and its therapeutic potential.

Dallas A, Vlassov AV.

Med Sci Monit. 2006 Apr;12(4):RA67-74. Epub 2006 Mar 28. Review.

PMID:
16572063
14.

Antisense- and RNA interference-based therapeutic strategies in allergy.

Popescu FD.

J Cell Mol Med. 2005 Oct-Dec;9(4):840-53. Review.

15.

Strategies to identify potential therapeutic target sites in RNA.

Lützelberger M, Kjems J.

Handb Exp Pharmacol. 2006;(173):243-59. Review.

PMID:
16594619
16.

siRNA-mediated antitumorigenesis for drug target validation and therapeutics.

Lu PY, Xie FY, Woodle MC.

Curr Opin Mol Ther. 2003 Jun;5(3):225-34. Review.

PMID:
12870431
17.

Efficient and isoform-selective inhibition of cellular gene expression by peptide nucleic acids.

Liu Y, Braasch DA, Nulf CJ, Corey DR.

Biochemistry. 2004 Feb 24;43(7):1921-7.

PMID:
14967032
18.

Nucleic acid modulation of gene expression: approaches for nucleic acid therapeutics against cancer.

Nakata Y, Kim TK, Shetzline S, Gewirtz AM.

Crit Rev Eukaryot Gene Expr. 2005;15(2):163-82. Review.

PMID:
16022634
19.

siRNA-based approaches in cancer therapy.

Devi GR.

Cancer Gene Ther. 2006 Sep;13(9):819-29. Epub 2006 Jan 20. Review.

PMID:
16424918
20.

Nucleic acid therapeutics: a work in progress.

Opalinska JB, Gewirtz AM.

Curr Opin Investig Drugs. 2002 Jun;3(6):928-33. Review. No abstract available.

PMID:
12137416

Supplemental Content

Support Center